Sign In

​​

Funds Managed by Mr. Sailesh Raj Bhan

Show All

Nippon India Large Cap FundAn open ended equity scheme predominantly investing in large cap stocksLatest NAV: 53.6192
(Oct 06 , 2022)



Product label

This product is suitable for investors who are seeking*:

  • Long term capital growth.
  • Investment predominantly into equity and equity related instruments of large cap companies.

*Investors should consult their investment advisers if in doubt about whether the product is suitable for them

Nippon India Multi Cap FundMulti Cap Fund - An open ended equity scheme investing across large cap, mid cap, small cap stocksLatest NAV: 165.9220
(Oct 06 , 2022)



NAV as on August 31​, 2022: `160.7135

​Performance of Nippon India Multi Cap Fund as on 31/08/2022
Particulars1 Year CAGR %3 Year CAGR %5 Year CAGR %Since Inception
Nippon India Multi Cap Fund16.5322.2713.4917.27
B:NIFTY 500 Multicap 50:25:25 TRI7.4823.9713.04NA
AB:S&P BSE Sensex TRI4.8218.1614.7515.13
Value of `10000 Invested
Nippon India Multi Cap Fund11,64818,29118,8251,60,713
B:NIFTY 500 Multicap 50:25:25 TRI10,74619,06218,454NA
AB:S&P BSE Sensex TRI10,48016,50419,8991,16,587
Inception Date: Mar 28, 2005
​​​B - Benchmark    |   AB - Additional Benchmark |   TRI - Total Return Index
Fund Manager: Sailesh Raj Bhan (Since Mar 2005), Ashutosh Bhargava (Co-Fund Manager)
NA has been mentioned as the benchmark data for corresponding period is not available.
​ ​​

​​PERFORMANCE OF OTHER OPEN ENDED SCHEMES MANAGED BY FUND MANAGER: Sailesh Raj Bhan

Scheme Name/sCAGR %
1 Year Return 3 Years Return5 Years Return
Scheme Benchmark Scheme Benchmark Scheme Benchmark
Nippon India Large Cap Fund11.196.5019.2019.3512.1713.53
Nippon India Pharma Fund-12.35-12.8225.0822.1517.5412.62
​​​​​

​​Note​:

a. Mr. Sailesh Raj Bhan manages 3 open-ended schemes of Nippon India Mutual Fund.

b. In case the number of schemes managed by a fund manager is more than six, in the performance data of other schemes, the top 3 and bottom 3 schemes managed by fund manager has been provided herein.

c. Period for which scheme’s performance has been provided is computed basis last day of the month-end preceding the date of advertisement.

d. Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan).

TRI - Total Returns Index reflects the returns on the index arising from (a) constituent stock price movements and (b) dividend receipts from constituent index stocks, thereby showing a true picture of returns.

The performance of the equity scheme is benchmarked to the Total Return variant of the Index.

​Mr. Sailesh Raj Bhan has been managing Nippon India Pharma Fund since Jun 2004, Nippon India Multi Cap Fund since Mar 2005, Nippon India Large Cap Fund since Aug 2007

PERFORMANCE OF OTHER OPEN ENDED SCHEMES MANAGED BY FUND MANAGER: Ashutosh Bhargava

Scheme Name/sCAGR %
1 Year Return 3 Years Return5 Years Return
Scheme Benchmark Scheme Benchmark Scheme Benchmark
Top 3
Nippon India Large Cap Fund#11.196.5019.2019.3512.1713.53
Nippon India Asset Allocator FoF6.854.92NANANANA
Nippon India Tax Saver (ELSS) Fund#6.086.7018.8420.835.6313.31
Bottom 3
Nippon India Quant Fund5.807.2319.5720.6911.5213.92
Nippon India Balanced Advantage Fund#4.314.9212.1714.088.7410.75
Nippon India Multi Asset Fund4.014.22NANANANA

Note:

a.Mr. Ashutosh Bhargava manages 7 open-ended scheme of Nippon India Mutual Fund.

b. In case the number of schemes managed by a fund manager is more than six, in the performance data of other schemes, the top 3 and bottom 3 schemes managed by fund manager has been provided herein.

c. Period for which scheme’s performance has been provided is computed basis last day of the month-end preceding the date of advertisement

d. Different plans shall have a different expense structure. The performance details provided herein are of Growth plan (Regular Plan).

TRI - Total Returns Index reflects the returns on the index arising from (a) constituent stock price movements and (b) dividend receipts from constituent index stocks, thereby showing a true picture of returns.

The performance of the equity scheme is benchmarked to the Total Return variant of the Index.

Mr. Ashutosh Bhargava has been managing Nippon India Balanced Advantage Fund since May 2018, Nippon India Quant Fund since Sep 2017, Nippon India Tax Saver (ELSS) Fund since july 2020, Nippon India Multi Asset Fund since Aug 2020,Nippon India Asset Allocator FoF since Feb 2021,Nippon India Multi Cap Fund since Sep 2021,Nippon India Large Cap Fund since Sep 2021.

​Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investments. Returns for 1 year and above are compounded annualized(CAGR) and returns less than 1 year are simple annualized basis. 6 months simple annualized returns ​are provided for the schemes that are in existence for more than 6 months but have not completed 1 year.IDCW (if any) are assumed to be reinvested at the prevailing NAV. In case of Nippon India ETF Liquid BeES, returns are based on gross IDCW per unit declared by the Fund. Bonus (if any) declared has been adjusted.Face value of schemes is `10 per unit, except for the schemes as specified here. Face Value of Nippon India Liquid Fund, Nippon India Money Market Fund Nippon India Ultra Short Duration Fund, Nippon India Low Duration Fund and Nippon India ETF Liquid BeES is `1000 per unit. Face value of Nippon India ETF Junior BeES is `1.25 per unit. Face value of Nippon India Overnight Fund is `100 per unit. Face Value of Nippon India ETF Nifty BeES, Nippon India ETF Bank BeES, Nippon India ETF PSU Bank BeES, Nippon India ETF NV20, Nippon India ETF Hang Seng BeES, Nippon India ETF Gold BeES is `1 per unit. In case, the start/end date of the concerned period is non-business day, NAV of the previous date is considered for computation of returns. Performance details of closed ended and interval schemes are not provided since these are not comparable with other schemes. Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan). ​​​​​​​​







​​​​​​ ​​ ​

​​​

Product label

This product is suitable for investors who are seeking*:

  • Long term capital growth.
  • Investment in equity and equity related securities.

*Investors should consult their investment advisers if in doubt about whether the product is suitable for them

Nippon India Pharma FundAn open ended equity scheme investing in pharma sectorLatest NAV: 287.3571
(Oct 06 , 2022)



NAV as on August 30, 2022: `276.2607

Performance of Nippon India Pharma Fund as on 31/08/2022
Particulars1 Year CAGR %3 Year CAGR %5 Year CAGR %Since Inception
Nippon India Pharma Fund-12.3525.0817.5419.95
B:S&P BSE Healthcare TRI-12.8222.1512.6214.44
AB:S&P BSE Sensex TRI4.8218.1614.7516.32
Value of `10000 Invested
Nippon India Pharma Fund8,76819,57822,4322,76,261
B:S&P BSE Healthcare TRI8,72118,23318,1191,17,281
AB:S&P BSE Sensex TRI10,48016,50419,8991,57,748
Inception Date: Jun 5, 2004
B - Benchmark    |   AB - Additional Benchmark |   TRI - Total Return Index
Fund Manager: Sailesh Raj Bhan (Since Jun 2004)
As TRI data is not available since Since Inception of the scheme, benchmark performance is calculated using composite CAGR of S&P BSE HC PRI values from date 04-Jun-2004 to date 23-Aug-2004 and TRI values since date 23-Aug-2004

PERFORMANCE OF OTHER OPEN ENDED SCHEMES MANAGED BY FUND MANAGER: Sailesh Raj Bhan

Scheme Name/sCAGR %
1 Year Return 3 Years Return5 Years Return
Scheme Benchmark Scheme Benchmark Scheme Benchmark
Nippon India Multi Cap Fund16.537.4822.2723.9713.4913.04
Nippon India Large Cap Fund11.196.5019.2019.3512.1713.53

Note:

a.Mr. Sailesh Raj Bhan manages 3 open-ended schemes of Nippon India Mutual Fund.

b. In case the number of schemes managed by a fund manager is more than six, in the performance data of other schemes, the top 3 and bottom 3 schemes managed by fund manager has been provided herein.

c. Period for which schemes performance has been provided is computed basis last day of the month-end preceding the date of advertisement.

d. Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan).

TRI - Total Returns Index reflects the returns on the index arising from (a) constituent stock price movements and (b) dividend receipts from constituent index stocks, thereby showing a true picture of returns.

The performance of the equity scheme is be​nchmarked to the Total Return variant of the Index.

Mr. Sailesh Raj Bhan has been managing Nippon India Pharma Fund since Jun 2004, Nippon India Multi Cap Fund since Mar 2005, Nippon India Large Cap Fund since Aug 2007

​Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investments. Returns for 1 year and above are compounded annualized(CAGR) and returns less than 1 year are simple annualized basis. 6 months simple annualized returns ​are provided for the schemes that are in existence for more than 6 months but have not completed 1 year.IDCW (if any) are assumed to be reinvested at the prevailing NAV. In case of Nippon India ETF Liquid BeES, returns are based on gross IDCW per unit declared by the Fund. Bonus (if any) declared has been adjusted.Face value of schemes is `10 per unit, except for the schemes as specified here. Face Value of Nippon India Liquid Fund, Nippon India Money Market Fund Nippon India Ultra Short Duration Fund, Nippon India Low Duration Fund and Nippon India ETF Liquid BeES is `1000 per unit. Face value of Nippon India ETF Junior BeES is `1.25 per unit. Face value of Nippon India Overnight Fund is `100 per unit. Face Value of Nippon India ETF Nifty BeES, Nippon India ETF Bank BeES, Nippon India ETF PSU Bank BeES, Nippon India ETF NV20, Nippon India ETF Hang Seng BeES, Nippon India ETF Gold BeES is `1 per unit. In case, the start/end date of the concerned period is non-business day, NAV of the previous date is considered for computation of returns. Performance details of closed ended and interval schemes are not provided since these are not comparable with other schemes. Different plans shall have a different expense structure. The performance details provided herein are of Growth Plan (Regular Plan). ​​​​​​​​









​​​​​​​​​​​

Product label

This product is suitable for investors who are seeking*:

  • Long term capital growth.
  • investment predominantly in equity and equity related Securities of pharma & other associated companies.

*Investors should consult their investment advisers if in doubt about whether the product is suitable for them

Get the app